Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PHOTORUACD

Financiado

Cerrado

Novel Photodissociable Ruthenium Based Anticancer Drugs

The discovery of cisplatin, cis-diamminedichloroplatinum(II), as an anticancer drug is a landmark of modern inorganic medicinal chemistry. Platinum drugs are the best-selling antitumor drugs in the world and they are effective in... ver más

30/06/2010

UNIVERSITY OF WARW...

178K€

Presupuesto del proyecto: 178K€

Líder del proyecto

UNIVERSITY OF WARWICK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2010-06-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITY OF WARWICK

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RUPROLIGHT Light activatable ruthenium based anticancer prodrugs 1M€ Cerrado

MET-EFFECT Metal complexes of a naturally inspired framework functional... 764K€ Cerrado

pepRu4PACT Ruthenium Peptide Bioconjugates for Photoactivated Chemother... Cerrado

PhoRAu Photochemistry and radiolabelling of gold III anticancer pr... 158K€ Cerrado

RYC-2011-07787 New photoactive metal complexes as dual anticancer drugs 184K€ Cerrado

RuPPIIs Ruthenium Based Protein Protein Interaction Inhibitor s 222K€ Cerrado

Líder del proyecto

UNIVERSITY OF WARWICK No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 178K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The discovery of cisplatin, cis-diamminedichloroplatinum(II), as an anticancer drug is a landmark of modern inorganic medicinal chemistry. Platinum drugs are the best-selling antitumor drugs in the world and they are effective in treating a variety of cancers. During the last decade, the search for new anticancer compounds has been widened to other transition metals. Ruthenium complexes in particular have shown considerable promise because of their rich synthetic chemistry, the range of oxidation states, the common octahedral geometry, and finally also because of their rich photochemistry. The fundamental goal of this project is to investigate the possibility of developing new types of hybrid ruthenium-based chemotherapeutic drugs that can be activated by irradiation with low-energy light. When irradiated these molecules form reactive aqua species and, at the same time, release biologically active ligands. The ligands can interfere with the cell cycle at a number of targets, while the metal-containing aqua species inhibit mitosis by binding to DNA. The proposed approach can lead to development of milder, more specific, and tunable drugs which can decrease the negative side-effects of chemotherapy. Inorganic and organic synthetic methodologies, advanced spectroscopic and analytical techniques will be used together with biochemical and medical methods to pursue the objectives of the project. The multi- and interdisciplinary nature of the research will prompt the applicant to acquire practical and theoretical skills on chemical biology and medical chemistry, to improve his independent thinking and leadership qualities, enhancing his scientific competencies and helping the applicant to attain an independent position.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores